GGrantIndex
Sort

48,018 grants matching immunotherapy

Collagen Binding MSCRAMMs

$419,265
Texas A&M University Health Science Ctr · R01 · FY2003 · AR

Using dietary glutamine supplementation for melanoma prevention and targeted therapy

$419,220
Mei Kong · University Of California-Irvine · R01 · FY2022 · CA

Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma

$419,207
Yibin Yang · Research Inst Of Fox Chase Can Ctr · R01 · FY2023 · CA

Role of IKK alpha in lymphoid organ development

$419,198
Yinling Hu · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells

$419,189
James Jackson · Tulane University Of Louisiana · R01 · FY2023 · CA

Induction of Tumor Immunity by Secreted HSP-gp96

$419,167
Eckhard R Podack · University Of Miami School Of Medicine · P01 · FY2007 · CA

Structure and Function of Heme-based Dioxygenases

$419,166
Syun-Ru Yeh · Albert Einstein College Of Medicine · R01 · FY2020 · GM

EGFRvIII-targeted Bispecific T cell Engagers for brain tumors

$419,152
John H Sampson · Duke University · R01 · FY2014 · NS

Human Monoclonal Antibodies against Botulinum Toxins

$419,084
Kim D Janda · Scripps Research Institute, The · U01 · FY2007 · AI

Leveraging combination histotripsy tumor ablation and N-dihydrogalactochitosan immunostimulation to advance osteosarcoma therapy

$419,080
Joanne Tuohy · Virginia Polytechnic Inst And St Univ · R21 · FY2025 · CA

Developmental Funds

$419,048
Helen E Heslop · Baylor College Of Medicine · P30 · FY2023 · CA

Developmental Funds

$419,048
C Kent Osborne · Baylor College Of Medicine · P30 · FY2020 · CA

Developmental Funds

$419,048
Helen E Heslop · Baylor College Of Medicine · P30 · FY2024 · CA

Developmental Funds

$419,048
Helen E Heslop · Baylor College Of Medicine · P30 · FY2022 · CA

Targeting TREM2 to boost anti-cancer therapy

$419,032
Marco Colonna · Washington University · R01 · FY2024 · CA

DPT-1 / TrialNet

$418,999
University Of Colorado Denver · U01 · FY2005 · DK

The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma

$418,946
Vu Nguyen Ngo · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA

Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T

$418,930
David A Scheinberg · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA

Immune surveillance in murine gammaherpesvirus infection

$418,918
Edward John Usherwood · Dartmouth College · R01 · FY2010 · CA

Impact of senescence on T-cell function and immunotherapeutic response

$418,905
Christin E Burd · Ohio State University · R01 · FY2019 · AG

Impact of senescence on T-cell function and immunotherapeutic response

$418,905
Christin E Burd · Ohio State University · R01 · FY2018 · AG

Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma

$418,885
Michael Richard Green · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention

$418,872
Ruth Lupu · Northshore University Healthsystem · R01 · FY2007 · CA

Cell migration and virological synapse formation in parenteral HIV transmission

$418,857
Benjamin K Chen · Icahn School Of Medicine At Mount Sinai · R01 · FY2016 · DA

Combining AD epitope vaccine with innate immunity

$418,833
University Of California Irvine · R01 · FY2005 · NS